<div id="readability-page-1"><div><ul> <li>On 13 May 2026, The Cigna Group’s President and COO Brian Evanko presented at the Bank of America Global Healthcare Conference, where the company reaffirmed its full-year 2026 outlook for consolidated adjusted income from operations of at least $30.35 per share and highlighted strong first-quarter results.</li> <li>Management also spotlighted efforts to simplify care, including reducing prior authorizations by roughly 15% and launching a rebate-free pharmacy service model, underscoring an emphasis on operational efficiency and patient access.</li> <li>We’ll now examine how Cigna’s reaffirmed earnings outlook and operational streamlining may shape the company’s existing investment narrative.</li> </ul><p>AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</p><h2>Cigna Group Investment Narrative Recap</h2><p>To own Cigna, you need to believe its scale in employer health plans and Evernorth’s pharmacy and health services can keep generating solid earnings while withstanding regulatory and cost pressure. The reaffirmed 2026 adjusted income from operations of at least US$30.35 per share supports the near term earnings catalyst, while the biggest ongoing risk remains potential regulatory and margin pressure on the Pharmacy Benefit Services model; this update does not materially change that risk profile.</p> <p>The company’s push to simplify care, including a roughly 15% reduction in medical prior authorizations and the launch of its rebate free Signature pharmacy model, ties directly into that earnings story. These operational changes sit alongside recent strong quarterly results and the reiterated 2026 outlook, giving investors more concrete data points around how Cigna is trying to sustain profitability while responding to client and regulatory scrutiny of affordability and PBM economics.</p> <p>Yet behind this reaffirmed guidance, investors should be aware of escalating scrutiny on PBM pricing and business practices that could...</p> <p>Read the full narrative on Cigna Group (it's free!)</p><p>Cigna Group's narrative projects $313.7 billion revenue and $7.8 billion earnings by 2029. This requires 4.1% yearly revenue growth and a $1.5 billion earnings increase from $6.3 billion today.</p><p>Uncover how Cigna Group's forecasts yield a $339.58 fair value, a 13% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a8d65f83-7380-4bee-b00e-d154535df4a5/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a8d65f83-7380-4bee-b00e-d154535df4a5/chart/quote-price"/><figcaption>CI 1-Year Stock Price Chart</figcaption></figure> <p>Nine fair value estimates from the Simply Wall St Community span roughly US$310 to US$869 per share, showing very different views on Cigna’s potential. When you contrast that spread with the central risk around regulatory pressure on Evernorth’s PBM economics, it underlines why many market participants weigh multiple scenarios for the company’s future performance.</p><p>Explore 9 other fair value estimates on Cigna Group - why the stock might be worth just $310.07!</p><h2>Decide For Yourself</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Cigna Group research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.</li><li>Our free Cigna Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cigna Group's overall financial health at a glance.</li></ul><h2>Want Some Alternatives?</h2><p>Every day counts. These free picks are already gaining attention. See them before the crowd does:</p><ul><li>Outshine the giants: these 16 early-stage AI stocks could fund your retirement.</li><li>Uncover the next big thing with 28 elite penny stocks that balance risk and reward.</li><li>Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

<p>Cigna Group's stock rose 6.6% following the reaffirmation of its 2026 outlook, projecting adjusted income of at least $30.35 per share. During a presentation at the Bank of America Global Healthcare Conference, President Brian Evanko highlighted strong Q1 results and efforts to streamline care, including a 15% reduction in prior authorizations and a new rebate-free pharmacy model. While the outlook supports near-term earnings, potential regulatory pressures on the Pharmacy Benefit Services model remain a concern. Cigna's revenue is projected to reach $313.7 billion by 2029, with a fair value estimate of $339.58, indicating a 13% upside from current prices.</p>

Simplywall

Cigna

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Why Cigna (CI) Is Up 6.6% After Reaffirming 2026 Outlook And Streamlining Care Delivery